Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Hippieslayer who wrote (14846)	2/12/1998 12:29:00 PM
From: Proton	Respond to of 32384

Re: CNBC and Accuracy There are times that CNBC doesn't get the facts straight...Maybe we should lobby for CNBC to get a full time biotech analyst so they can accurately relate the facts. Please, no! CNBC accuracy arbitrage can make you a lot of money, I kid you not. Check all reports CNBC makes (Bartiromo, Pisani, Kernan, Faber, Winners & Losers, Earnings Reports) against the actual press or news release (when there is one). Perhaps 5-15% of the time, there is an inaccuracy or (more commonly) an omission that will produce a temporary inefficiency in the market. Witness LGND today. Of course, now "everyone" will do it, and CNBC will become more careful, so, like all arbitrage, this one will become unprofitable. :-) Anyway, can you trust an outfit that squirts green slime up the side of your screen? :-O Pý

To: Hippieslayer who wrote (14846)	2/12/1998 1:24:00 PM
From: tonyt	Read Replies (1) \| Respond to of 32384

Ligand (NASDAQ:LGND) rises on positive data ========================================================== LOS ANGELES, Feb 12 (Reuters) - Shares of Ligand Pharmaceuticals Inc rose in active volume Thursday after the release earlier in the week of positive data on two of the company's leading drug candidates, analysts said. They said they are particularly encouraged by a study showing Ligand's Targretin drug for cancer was more effective than the leading breast cancer drug on the market, in tests on rats. Shares of Ligand were up 1-1/4 to 14-5/8. Ligand has Targretin in advanced clinical trials for cutaneous t-cell lymphoma, a rare form of cancer, and is also testing it in lung, ovarian, and head and neck cancer. Van den Broek said the lymphoma indication for which Targretin was most likely to win initial Food and Drug Administration approval was a rare form of cancer, but positive data in other more common types of cancers might lead to more off-label uses. But some analysts questioned the usefulness of rat data. "It always amazes me that people can get excited about rat data since it is not really predictive of how a drug will work in humans," said Americal Securities analyst Charles Engelberg.